PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193434
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193434
Next Generation Bio-therapeutics Market size was valued at USD 78,400.6 Million in 2022, expanding at a CAGR of 10.1% from 2023 to 2030.
Next-generation biotherapeutics are improved versions of currently marketed treatments that, although acting on the same target cell, tissue, or organ, have additional features as a result of antibody conjugation, radiolabeling, PEGylation, and glycol-conjugation.
The global market for next generation biotherapeutics is expected to grow over the next few years as a result of the ongoing need for cutting-edge medications. The development of the worldwide next generation biotherapeutics market during the coming few years will be aided by procedures including gene therapy, monoclonal antibodies (mAb), gene silencing, DNA & RNA editing technologies, and stem cell therapy. Many biopharmaceutical companies are eschewing conventional monoclonal antibody therapeutics in favor of novel genetic therapies and utilizing complex antibody architectures.
Further, the US Food and Drug Administration (FDA) oversees approving any medications before they can be used and sold to the general public. Following several stages of clinical trials, a drug's production, and finalization for the treatment of a certain symptom or disease is carried out. Any medicine that has been manufactured must go through several tests and investigations. While protecting the integrity of the trials and the test subjects at risk, the research should examine the chemical, physical, emotional, and other consequences of that specific drug on animals, humans, people with diseases, and people without diseases. The FDA's clearance of medications and the rising number of clinical trials are anticipated to aid in the development of the next generation biotherapeutics globally.
The Global Next Generation Bio-therapeutics Market is segmented on the basis of Technology, Application, End User, and Region.
The market is split into four categories based on Technology: antibody-drug conjugates, bispecific antibodies, antibody fragments, and others. The antibody fragments segment dominates the market. Growing demand for antibody fragments such as protein antibodies is mainly contributing to segment growth.
The market is segmented into three categories based on application: oncology, autoimmune/ inflammatory diseases, and others. The oncology segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the demand for therapy-based diagnostics.
The market is segmented into four categories based on end user: clinical research, hospitals, pharma & biotech, and others. The clinical research segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the number of research project activities in next generation bio-therapeutics is boosting the segment growth.
The worldwide market for Next Generation Bio-therapeutics is vastly fragmented in nature which comprised of large and small-sized market players with few large dominating the global market share. The companies in market emphasize on adopting aggressive strategies to reach out large consumer base. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new technology launches, partnerships, distribution network development, R&D spending, and mergers and acquisitions.
For instance, in September 2023, Novartis invested in early technical development capabilities for enhancing its next generation biotherapeutics.
Key features of the study:
This proposed research study on Next Generation Bio-therapeutics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Next Generation Bio-therapeutics market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Next Generation Bio-therapeutics market
Impact of COVID-19 on Next Generation Bio-therapeutics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Next Generation Bio-therapeutics market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Next Generation Bio-therapeutics market, we have also included competitive landscape and key innovator analysis for the Next Generation Bio-therapeutics market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Next Generation Bio-therapeutics market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global Next Generation Bio-therapeutics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEXT GENERATION BIO-THERAPEUTICS MARKET KEY PLAYERS
Regenxbio & Neurimmune AG
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche AG
Kyowa Kirin Co., Ltd
Seattle Genetics, Inc
Ono Pharmaceuticals Co, Ltd
Johnson & Johnson Services, Inc.
Sun Pharmaceutical Industries Ltd.
GLOBAL NEXT GENERATION BIO-THERAPEUTICS MARKET, BY TECHNOLOGY
GLOBAL NEXT GENERATION BIO-THERAPEUTICS MARKET, BY APPLICATION
Autoimmune/ Inflammatory Diseases
GLOBAL NEXT GENERATION BIO-THERAPEUTICS MARKET, BY END USER
Pharma & biotech
GLOBAL NEXT GENERATION BIO-THERAPEUTICS MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA